Literature DB >> 3455830

Prognostic significance of some clinical, morphological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts.

G Kerndrup, B Pedersen, J Ellegaard, P Hokland.   

Abstract

In 27 patients initially diagnosed as refractory anaemia (RA) or RA with sideroblasts (RA-S) according to the FAB-classification a number of clinical, morphological and cytogenetic parameters were correlated for prognostic significance. From these correlations it emerged that severe cytopenia is centrally positioned with regard to clinical course in RA and RA-S. Positive correlations were found to initial diagnosis, clonal cytogenetic abnormalities, progression to RA with an excess of blasts (RAEB) or acute myeloid leukaemia (AML), the percentage of bone marrow blast cells and prolonged half life for radioactively labeled iron. The degree of peripheral blood granulocytopenia, alone, was correlated to bone marrow hypoplasia. Moreover, the frequency of abnormal karyotypes was inversely correlated to bone marrow cellularity and proportional to the frequency of bone marrow blast cells. From these relationships it may be proposed that chromosome abnormalities are associated with prolonged blast cell generation times and inhibition of blast cell maturation resulting in reduced marrow cellularity and blast cell accumulation, and, in the peripheral blood, falling percentages of neutrophil granulocytes. With the blast cell accumulation the bone marrow cellularity again becomes hyperplastic and the preleukaemic condition is transformed into RAEB or AML.

Entities:  

Mesh:

Year:  1986        PMID: 3455830     DOI: 10.1007/BF00320140

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  22 in total

1.  The preleukemic syndrome: correlation of in vitro parameters of granulopoiesis with clinical features.

Authors:  P L Greenberg; B Mara
Journal:  Am J Med       Date:  1979-06       Impact factor: 4.965

2.  Specific minor chromosome deletions consistently occurring in myelodysplastic syndromes.

Authors:  B Pedersen; G Kerndrup
Journal:  Cancer Genet Cytogenet       Date:  1986-09

3.  In vitro agar culture patterns in preleukemia and their clinical significance.

Authors:  D S Verma; G Spitzer; K A Dicke; K B McCredie
Journal:  Leuk Res       Date:  1979       Impact factor: 3.156

4.  Myelodysplastic syndromes: a scoring system with prognostic significance.

Authors:  G J Mufti; J R Stevens; D G Oscier; T J Hamblin; D Machin
Journal:  Br J Haematol       Date:  1985-03       Impact factor: 6.998

5.  Erythrokinetics and androgens in bone marrow cancer.

Authors:  R Alexanian; C P Alfrey
Journal:  Cancer       Date:  1976-08       Impact factor: 6.860

6.  Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia.

Authors:  D J Weisdorf; M M Oken; G J Johnson; R E Rydell
Journal:  Br J Haematol       Date:  1983-12       Impact factor: 6.998

7.  Proliferative activity of bone marrow cells in primary dysmyelopoietic (preleukemic) syndromes.

Authors:  C Montecucco; A Riccardi; E Traversi; P Giordano; G Mazzini; E Ascari
Journal:  Cancer       Date:  1983-10-01       Impact factor: 6.860

8.  Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS.

Authors:  G Tricot; C De Wolf-Peeters; R Vlietinck; R L Verwilghen
Journal:  Br J Haematol       Date:  1984-10       Impact factor: 6.998

9.  Human preleukemia.

Authors:  H P Koeffler; D W Golde
Journal:  Ann Intern Med       Date:  1980-08       Impact factor: 25.391

10.  The prognostic value of chromosome studies in patients with the preleukemic syndrome (hemopoietic dysplasia).

Authors:  R L Anderson; G C Bagby
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

View more
  1 in total

1.  The prognostic significance of cytological, histological and cytogenetic findings in refractory anaemia (RA) and RA with sideroblasts. A follow up study.

Authors:  G Kerndrup; K Bendix-Hansen; B Pedersen
Journal:  Blut       Date:  1987-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.